660 related articles for article (PubMed ID: 32364568)
1. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F
JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568
[TBL] [Abstract][Full Text] [Related]
2. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis.
Zingariello CD; Elder ME; Kang PB
Pediatr Neurol; 2020 Oct; 111():40-43. PubMed ID: 32951658
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial.
Piehl F; Eriksson-Dufva A; Budzianowska A; Feresiadou A; Hansson W; Hietala MA; Håkansson I; Johansson R; Jons D; Kmezic I; Lindberg C; Lindh J; Lundin F; Nygren I; Punga AR; Press R; Samuelsson K; Sundström P; Wickberg O; Brauner S; Frisell T
JAMA Neurol; 2022 Nov; 79(11):1105-1112. PubMed ID: 36121672
[TBL] [Abstract][Full Text] [Related]
4. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients.
Afanasiev V; Demeret S; Bolgert F; Eymard B; Laforêt P; Benveniste O
Neuromuscul Disord; 2017 Mar; 27(3):251-258. PubMed ID: 28082209
[TBL] [Abstract][Full Text] [Related]
5. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study.
Singh N; Goyal V
J Neurol; 2019 Jul; 266(7):1596-1600. PubMed ID: 30919039
[TBL] [Abstract][Full Text] [Related]
6. Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis.
Robeson KR; Kumar A; Keung B; DiCapua DB; Grodinsky E; Patwa HS; Stathopoulos PA; Goldstein JM; O'Connor KC; Nowak RJ
JAMA Neurol; 2017 Jan; 74(1):60-66. PubMed ID: 27893014
[TBL] [Abstract][Full Text] [Related]
7. Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.
Sudulagunta SR; Sepehrar M; Sodalagunta MB; Settikere Nataraju A; Bangalore Raja SK; Sathyanarayana D; Gummadi S; Burra HK
Ger Med Sci; 2016; 14():Doc12. PubMed ID: 27790079
[No Abstract] [Full Text] [Related]
8. Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience.
Molimard A; Gitiaux C; Barnerias C; Audic F; Isapof A; Walther-Louvier U; Cances C; Espil-Taris C; Davion JB; Quijano-Roy S; Grisel C; Chabrol B; Desguerre I
Neurology; 2022 Jun; 98(23):e2368-e2376. PubMed ID: 35314497
[TBL] [Abstract][Full Text] [Related]
9. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis.
Lu J; Zhong H; Jing S; Wang L; Xi J; Lu J; Zhou L; Zhao C
Muscle Nerve; 2020 Mar; 61(3):311-315. PubMed ID: 31875994
[TBL] [Abstract][Full Text] [Related]
10. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W
J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616
[TBL] [Abstract][Full Text] [Related]
11. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
Li H; Huang Z; Jia D; Xue H; Pan J; Zhang M; Shi K; Shi FD; Zhang C
J Neuroimmunol; 2021 May; 354():577528. PubMed ID: 33662696
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy choice and maintenance for generalized myasthenia gravis in China.
Zhang C; Bu B; Yang H; Wang L; Liu W; Duan RS; Zhang M; Zeng P; Du C; Yang L; Shi FD
CNS Neurosci Ther; 2020 Dec; 26(12):1241-1254. PubMed ID: 33103369
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
14. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
Du Y; Li C; Hao YF; Zhao C; Yan Q; Yao D; Li L; Zhang W
J Neurol; 2022 Aug; 269(8):4229-4240. PubMed ID: 35243555
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS
J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791
[TBL] [Abstract][Full Text] [Related]
16. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Efficacy and Safety of Low-Dose Rituximab in Patients with Refractory Myasthenia Gravis.
Ren J; Wang J; Liu R; Jin Y; Guo J; Yao Y; Luo J; Hao H; Gao F
Eur Neurol; 2023; 86(6):387-394. PubMed ID: 37778340
[TBL] [Abstract][Full Text] [Related]
19. Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome.
Cortés-Vicente E; Álvarez-Velasco R; Pla-Junca F; Rojas-Garcia R; Paradas C; Sevilla T; Casasnovas C; Gómez-Caravaca MT; Pardo J; Ramos-Fransi A; Pelayo-Negro AL; Gutiérrez-Gutiérrez G; Turon-Sans J; López de Munain A; Guerrero-Sola A; Jericó I; Martín MA; Mendoza MD; Morís G; Vélez-Gómez B; Garcia-Sobrino T; Pascual-Goñi E; Reyes-Leiva D; Illa I; Gallardo E
Ann Clin Transl Neurol; 2022 Feb; 9(2):122-131. PubMed ID: 35080153
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis.
Nagia L; Lemos J; Abusamra K; Cornblath WT; Eggenberger ER
Ophthalmology; 2015 Jul; 122(7):1517-21. PubMed ID: 25892018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
